The multiple functions of miR-574-5p in the neuroblastoma tumor microenvironment.
NSCLC
PGE2
TLR7/8
miR-574-5p
neuroblastoma
tetraspanins
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
07
08
2023
medline:
21
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
Neuroblastoma is the most common extracranial solid tumor in childhood and arises from neural crest cells of the developing sympathetic nervous system. Prostaglandin E
Identifiants
pubmed: 37731742
doi: 10.3389/fphar.2023.1183720
pii: 1183720
pmc: PMC10507178
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1183720Informations de copyright
Copyright © 2023 Proestler, Donzelli, Nevermann, Breitwieser, Koch, Best, Fauth, Wickström, Harter, Kogner, Lavieu, Larsson and Saul.
Déclaration de conflit d'intérêts
TB was employed by Merck KGaA. MF was employed by Prolytic GmbH, a Kymos Company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2010 Sep 30;363(14):1313-23
pubmed: 20879880
J Extracell Vesicles. 2021 May;10(7):e12082
pubmed: 34012515
Front Immunol. 2014 Sep 16;5:442
pubmed: 25278937
Int J Cancer. 2016 Jan 1;138(1):14-21
pubmed: 25559768
Front Immunol. 2020 Oct 14;11:585282
pubmed: 33154755
J Extracell Vesicles. 2019 Aug 1;8(1):1648167
pubmed: 31489144
Int J Biochem Cell Biol. 2012 Sep;44(9):1574-84
pubmed: 22728313
Cell Biosci. 2019 Feb 15;9:19
pubmed: 30815248
EBioMedicine. 2018 Jun;32:84-92
pubmed: 29804818
Cell Immunol. 2011;271(2):401-12
pubmed: 21889130
J Extracell Vesicles. 2021 Oct;10(12):e12143
pubmed: 34596365
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Front Immunol. 2020 Mar 31;11:531
pubmed: 32296437
J Clin Oncol. 2009 Jan 10;27(2):289-97
pubmed: 19047291
J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9
pubmed: 10363850
Int J Nanomedicine. 2017 Jul 06;12:4823-4833
pubmed: 28740388
Int J Cancer. 2013 Nov 15;133(10):2296-306
pubmed: 23649556
J Circ Biomark. 2015 Jul 17;4:7
pubmed: 28936243
BMC Cancer. 2018 Jan 6;18(1):47
pubmed: 29306323
J Vis Exp. 2011 May 06;(51):
pubmed: 21587162
FASEB J. 2019 Jun;33(6):6933-6947
pubmed: 30922080
Mol Cancer. 2017 Jun 29;16(1):114
pubmed: 28662712
Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11
pubmed: 16314869
Signal Transduct Target Ther. 2020 Aug 5;5(1):145
pubmed: 32759948
Gut. 2006 Jan;55(1):115-22
pubmed: 16118353
Cancer Prev Res (Phila). 2020 Oct;13(10):877-888
pubmed: 32718943
J Virol. 2001 Mar;75(5):2235-45
pubmed: 11160727
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Cancers (Basel). 2021 Apr 23;13(9):
pubmed: 33922795
Dev Cell. 2011 Oct 18;21(4):708-21
pubmed: 21962903
J Extracell Vesicles. 2014 Mar 26;3:
pubmed: 24683445
J Biol Chem. 2000 Oct 20;275(42):32783-92
pubmed: 10869354
Nat Commun. 2021 Mar 25;12(1):1864
pubmed: 33767144
FASEB J. 2020 Aug;34(8):11101-11114
pubmed: 32623799
Cancer Treat Rev. 2018 Apr;65:22-32
pubmed: 29502037
Front Mol Neurosci. 2019 Jan 29;12:9
pubmed: 30760980
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Oncol Rep. 2005 Apr;13(4):559-83
pubmed: 15756426
Adv Exp Med Biol. 2019;1161:89-100
pubmed: 31562624
Semin Immunopathol. 2013 Mar;35(2):123-37
pubmed: 22996682
PLoS One. 2015 Feb 19;10(2):e0116703
pubmed: 25695778
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2110-6
pubmed: 22753494
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Nat Med. 2002 Mar;8(3):289-93
pubmed: 11875501
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18757-62
pubmed: 19846775
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Cells. 2020 Jul 02;9(7):
pubmed: 32630649
Ann Surg. 2012 Oct;256(4):573-80
pubmed: 22964741
J Exp Med. 2020 Feb 13;217(3):e20190103
pubmed: 32997468
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117-1122
pubmed: 28096371
Cancers (Basel). 2020 Oct 10;12(10):
pubmed: 33050533
J Cell Biol. 2020 Mar 2;219(3):
pubmed: 32049272
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Front Pharmacol. 2023 Feb 16;14:1114295
pubmed: 36874032
Mol Cell Biochem. 2020 Apr;467(1-2):77-94
pubmed: 32088833
Int J Mol Sci. 2022 Aug 01;23(15):
pubmed: 35955677
Front Pharmacol. 2019 Jul 19;10:824
pubmed: 31379585
Front Pharmacol. 2020 Mar 13;11:196
pubmed: 32231562
Adv Biol Regul. 2020 Jan;75:100653
pubmed: 31594701
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8070-5
pubmed: 26080408
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Annu Rev Cell Dev Biol. 2003;19:397-422
pubmed: 14570575
Children (Basel). 2018 Aug 28;5(9):
pubmed: 30154341
Tumour Biol. 2015 Jun;36(6):4583-9
pubmed: 25619475
Ultrastruct Pathol. 1995 Jul-Aug;19(4):311-22
pubmed: 7571090
Oncoimmunology. 2019 Feb 19;8(5):e1574198
pubmed: 31069133
Pharmacol Rev. 2007 Sep;59(3):207-24
pubmed: 17878511
Int J Mol Sci. 2021 Apr 12;22(8):
pubmed: 33921337
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
FASEB Bioadv. 2019 Jul 01;1(8):481-492
pubmed: 32123845